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Inhibition of Aminoglycoside Acetyltransferase Resistance Enzymes by
Metal Salts
Yijia Li, Keith D. Green, Brooke R. Johnson, Sylvie Garneau-Tsodikova
Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA
Aminoglycosides (AGs) are clinically relevant antibiotics used to treat infections caused by both Gram-negative and Gram-posi-
tive bacteria, as well asMycobacteria. As with all current antibacterial agents, resistance to AGs is an increasing problem. The
most commonmechanism of resistance to AGs is the presence of AG-modifying enzymes (AMEs) in bacterial cells, with AG
acetyltransferases (AACs) being the most prevalent. Recently, it was discovered that Zn2metal ions displayed an inhibitory ef-
fect on the resistance enzyme AAC(6=)-Ib in Acinetobacter baumannii and Escherichia coli. In this study, we explore a wide array
of metal salts (Mg2, Cr3, Cr6, Mn2, Co2, Ni2, Cu2, Zn2, Cd2, and Au3with different counter ions) and their inhibi-
tory effect on a large repertoire of AACs [AAC(2=)-Ic, AAC(3)-Ia, AAC(3)-Ib, AAC(3)-IV, AAC(6=)-Ib=, AAC(6=)-Ie, AAC(6=)-IId,
and Eis]. In addition, we determine theMIC values for amikacin and tobramycin in combination with a zinc pyrithione complex
in clinical isolates of various bacterial strains (two strains of A. baumannii, three of Enterobacter cloacae, and four of Klebsiella
pneumoniae) and one representative of each species purchased from the American Type Culture Collection.
Aminoglycosides (AGs) are broad-spectrum bactericidal anti-biotics that are used clinically for the treatment of serious
bacterial infections (1, 2). These antibiotics were originally iso-
lated from Streptomyces and Micromonospora (3) and display ac-
tivity against Gram-positive bacteria, aerobic Gram-negative
pathogenic bacteria, and Mycobacteria. Since the discovery of
streptomycin, the first-in-class AG isolated, many AGs have been
discovered and developed with improved efficacy. This property
has kept them clinically relevant despite their inherent oto- and
nephrotoxicity. Currently, amikacin (AMK), gentamicin (GEN),
and tobramycin (TOB) are the most commonly prescribed AGs
for systemic administration in the United States against bacterial
infections (see Fig. S1 in the supplemental material) (4). Another
AG, kanamycin A (KAN), is also used systemically but only to
treat resistant strains of Mycobacterium tuberculosis in patients
who show no response to first-line antituberculosis treatments.
Other AGs, such as neomycin B (NEO), are found in antibiotic
ointment formulations for topical use (5).
The increased importance and popularity of AGs have, unfor-
tunately, led to lapses in antimicrobial stewardship. This has ac-
celerated the development of resistance against AGs and reduced
the effective agents available for combating ever-evolving patho-
gens. Themost commonmechanismof bacterial resistance toAGs
is the acquisition of AG-modifying enzymes (AMEs) (6, 7). Based
on the reactions that they catalyze, AMEs can be classified as AG
N-acetyltransferases (AACs), AGO-phosphotransferases (APHs),
or AGO-nucleotidyltransferases (ANTs), among which AACs are
responsible for the majority of resistant infections. AACs modify
AG substrates and disrupt their binding to the ribosome by trans-
ferring the acetyl group from acetyl coenzyme A (AcCoA) onto
amine moieties of the AG scaffolds. Although most AACs are re-
giospecific and modify only a single amino group, the unique
enhanced intracellular survival (Eis) protein upregulated in resis-
tantM. tuberculosis strains is capable of acetylating AG substrates
at several different positions (8–10).
In an effort to overcome bacterial resistance, a large amount of
time and money has been invested toward the development of
inhibitors of these resistance enzymes. Most commonly, small or-
ganicmolecules have been explored for this purpose. For example,
in silico and high-throughput screening was used to identify small
organic molecules capable of inhibiting AAC(6=)-Ib (11) and Eis
(12), respectively. Traditional synthesis was utilized to generate a
library of 45 noncarbohydrate molecules containing a 1,3-di-
amine scaffold commonly found in AGs, which were found to be
competitive inhibitors of APH(3=)-IIIa (13). Bisubstrate inhibi-
tors comprised of an AG (GEN or neamine) linked to an AcCoA-
like molecule were also found to inhibit various AAC(3) and
AAC(6=) resistance enzymes (14, 15).
Interestingly, Zn2metal ionswere recently reported to inhibit
AAC(6=)-Ib and reduce AMK resistance inAcinetobacter bauman-
nii and Escherichia coli (16). Inspired by this study, we aimed to
decipher whether metal ions could be used to inhibit a larger rep-
ertoire of AACs in a variety of bacterial strains. Here, we explore
the possibility of using Zn2 and other ions (Mg2, Cr3, Cr6,
Mn2, Co2, Ni2, Cu2, Cd2, and Au3 in different salt forms)
to inhibit various AACs, including AAC(2=)-Ic (fromM. tubercu-
losis) (17, 18), AAC(3)-Ia (from Serratia marcescens) (19),
AAC(3)-Ib from the bifunctional AAC(3)-Ib/AAC(6=)-Ib= (from
Pseudomonas aeruginosa) (20, 21), AAC(3)-IV (from E. coli) (22),
AAC(6=)-Ib= from the bifunctional AAC(3)-Ib/AAC(6=)-Ib=
(from P. aeruginosa) (20, 21), AAC(6=)-Ie from the bifunctional
enzyme AAC(6=)-Ie/APH(2)-Ia (from Staphylococcus aureus)
(23–25), AAC(6=)-IId from the bifunctional ANT(3)-Ii/
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AAC(6=)-IId (from S. marcescens) (26, 27), and Eis (from M. tu-
berculosis) (8). We also present MIC data for AMK and TOB in
combination with a zinc complex, zinc pyrithione (ZnPT).
MATERIALS AND METHODS
Materials and instrumentation. With the exception of AAC(3)-Ia, for
which the cloning, overexpression, and purification are described below,
all of the enzymes involved in this study, AAC(2=)-Ic (8), AAC(3)-Ib (28),
AAC(3)-IV (29), AAC(6=)-Ie/APH(2)-Ia (29), AAC(6=)-Ib= (28),
AAC(6=)-IId (30), and Eis (8), were expressed and purified as previously
described. Here, AAC(6=)-Ie/APH(2)-Ia was studied solely for its
AAC(6=) activity and is referred to as AAC(6=)-Ie throughout the manu-
script. The S.marcescens genomicDNAused to clone AAC(3)-Ia was a gift
from Paul H. Roy (Université Laval, Québec, Canada). Primers for PCR
were purchased from IDT (Coralville, IA). Ladders for DNA agarose gels
as well as cloning enzymes, including Phusion DNA polymerase, restric-
tion endonucleases, and T4 DNA ligase, were purchased from New Eng-
land BioLabs (NEB; Ipswich, MA). The pET28a vector was purchased
fromNovagen (Gibbstown,NJ). TOP10 and BL21(DE3) chemically com-
petent E. coli cells were purchased from Invitrogen (Carlsbad, CA). The
NiII-nitrilotriacetic acid (NTA) resin used for affinity chromatography
was purchased from Qiagen (Valencia, CA). The AcCoA; 4,4=-dithio-
dipyridine (DTDP); 5,5=-dithiobis-(2-nitrobenzoic acid) (DTNB); all
metal salts [MgCl2, CrCl3, CrO3, MnSO4, CoCl2, NiCl2, NiSO4,
Cu(OAc)2, Cu(NO3)2, CuSO4, Zn(OAc)2, ZnCl2, ZnBr2, ZnSO4, CdCl2,
CdSO4, and AuCl3]; and the AGs AMK, GEN, and sisomicin (SIS) were
purchased from Sigma-Aldrich (Milwaukee, WI). The AGs KAN, NEO,
netilmicin (NET), and TOB were purchased from AK Scientific (Moun-
tain View, CA) (see Fig. S1 in the supplemental material). Ninety-six-well
plates were purchased from Thermo Fisher Scientific (Waltham, MA).
UV-visible (UV-Vis) assays were monitored on a multimode SpectraMax
M5 plate reader.
Previously identified bacterial strains were obtained from the Ameri-
can Type Culture Collection (ATCC), including A. baumannii ATCC
19606, Enterobacter cloacae ATCC 13047, and Klebsiella pneumoniae
ATCC 27736. Clinical isolates of A. baumannii (isolates 75 and 81), E.
cloacae (isolates 41, 52, and 61), and K. pneumoniae (isolates 22, 24, 34,
and 44) were obtained from themicrobiology laboratory at theUniversity
of Kentucky Hospital System. Known resistance profiles of the clinical
isolates are presented in Table 1.
Cloning, overexpression, andpurificationofAAC(3)-Ia (NHis).The
aac(3)-Ia gene was PCR amplified from S. marcescens genomic DNA by
using forward primer 5=-CGATACCATATGTTACGCAGCAGCAACGA
TG-3= and reverse primer 5=-TTGAACCTCGAGTTAGGTGGCGGTAC-
3=. The amplified fragment was digested by using the NdeI and XhoI
restriction enzymes (cut sites are underlined in the primer sequences) and
ligated into the linearized pET28a vector. The ligated pAAC(3)-
Ia-pET28a plasmid was transformed into E. coli TOP10 chemically com-
petent cells for plasmid replication and then into E. coliBL21(DE3) chem-
ically competent cells for protein overexpression. After confirmation of its
DNA sequence, a fresh transformant of the pAAC(3)-Ia-pET28a plasmid
was grown in LB broth (KAN, 50g/ml) (3 liters) at 37°C with shaking at
200 rpm until the optical density at an attenuance of 600 nm reached 0.6.
The protein expression was induced with 1 mM (final concentration)
IPTG (isopropyl--D-thiogalactopyranoside). After induction, bacteria
were kept growing overnight at 20°C. The desired AAC(3)-Ia protein was
then purified using NiII-NTA affinity column chromatography in 25 mM
Tris-HCl (pH 8.0) (adjusted at room temperature [RT]), 200 mM NaCl,
and 10% glycerol with a gradient of imidazole (10 ml of 5 mM imidazole
and 3 times with 5 ml each of 20 mM, 40 mM, and 200 mM imidazole).
Pure fractions, as determined by SDS-PAGE (see Fig. S2 in the supple-
mental material), were dialyzed in Tris-HCl (50 mM, pH 8.0), NaCl (300
mM), and glycerol (10%); flash-frozen in liquid nitrogen; and stored at
80°C after concentrating using an Amicon (10,000-molecular-weight-
cutoff [MWCO]) ultracentrifugal filter cellulose protein concentrator.
Protein purification yielded 0.5 mg of AAC(3)-Ia per liter of culture.
Determinationof inhibitionofAACenzymesby variousmetal salts.
To determine the inhibition of various AACs by different metal salts, we
performed UV-Vis assays in 96-well plates. Each reaction mixture (200
l) containedmetal salts (1mM), AGs (100M), AcCoA (500Mfor Eis
and 150M for all other AACs), indicator (DTNB or DTDP; 2 mM), and
enzyme [0.5Mfor AAC(6=) enzymes, AAC(3)-Ib, AAC(3)-Ia, and Eis or
0.125M for AAC(2=)-Ic and AAC(3)-IV] in the appropriate buffer [100
mM K2HPO4 for AAC(2=)-Ic; 50 mM Tris-HCl (pH 8.0) for Eis; 50 mM
2-(N-morpholino)ethanesulfonic acid (MES) (pH 6.6) for AAC(3)-Ia,
AAC(3)-Ib, AAC(3)-IV, andAAC(6=)-Ie; and 50mMHEPES (pH7.5) for
AAC(6=)-Ib= and AAC(6=)-IId]. The pH of all buffers was adjusted at RT.
Reactions were carried out at 25°C for all enzymes except for AAC(6=)-Ie,
where reactions were performed at 37°C. DTNB was used to monitor
reaction progress with all enzymes, except with AAC(6=)-Ib= and
AAC(6=)-IId, where DTDP was used. Reaction mixtures containing
DTDP were monitored at 324 nm (ε  19,800 M1 cm1), and those
containing DTNB were monitored at 412 nm (ε  14,150 M1 cm1).
Absorbance was recorded every 30 s for 20 min. Enzyme activities were
TABLE 1 Resistance profiles of clinical isolates against the three AGs used for treatment of systemic infections in the United States as well as other
clinically relevant antibiotics
Species and isolate
designation
MIC (g/ml) of druga:
AMK GEN TOB AZA CFPM CFX CFZ CEFX CIP LEV MER NTF TET
A. baumannii
75 128 8 8 16 16 16 16 32 0.2 4 8 64 8
81 4 8 2 16 16 16 16 32 2 4 8 64 8
E. cloacae
41 8 8 8 16 16 16 16 32 1 1 8 64 8
52 1–2 8 8 16 16 16 8 32 2 4 8 32 8
61 4–8 8 8 16 1 16 16 16 2 4 1 64 8
K. pneumoniae
22 32 8 8 16 16 16 16 32 2 4 1 64 8
24 16 8 8 16 16 16 16 32 2 4 2 64 4
34 1 2 2 2 1 4 2 32 0.5 1 1 64 2
44 16 8 8 16 1 16 16 32 	2 4 8 64 8
a Abbreviations: AZA, aztreonam; CFPM, cefepime; CFX, cefoxitin; CFZ, ceftazidime; CEFX, ceftriaxone; CIP, ciprofloxacin; LEV, levofloxacin; MER, meropenem; NTF,
nitrofurantoin; TET, tetracycline.
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determined by calculating the initial reaction rates using the first 2 to 5
min of the reaction (Fig. 1; also see Fig. S3 and Table S1 in the supplemen-
talmaterial). NEO andTOB are not substrates of AAC(3)-Ia andAAC(3)-
Ib. In addition, NET is not a substrate of AAC(3)-Ib. Therefore, these AGs
were not tested with the two AAC(3)s listed above. All experiments were
performed in triplicate.
TLC. Some metals in this study can have high affinities for free thiols
that are detected by the UV-Vis assay as indicative of acetylation of AGs.
Therefore, we performed thin-layer chromatography (TLC) experiments
to further confirm that metal salts would exert inhibition directly on the
conversion from parent to acetylated AGs and not only react with the
CoASH that would be generated during this conversion, which would
nullify our results. Reaction mixtures (20 l) contained 50 mM buffer
[HEPES (pH7.5) for AAC(6=)-Ib= andAAC(6=)-IId andMES (pH6.6) for
other enzymes, pH adjusted at RT], 0.2mMAGs, 0.24mMAcCoA, 1mM
metal salts, and 1Menzyme. Reactionmixtureswere incubated for 1 h at
37°C [for AAC(6=)-Ie] or 25°C (for all other enzymes). All 20 l of reac-
tion mixtures was loaded onto TLC plates (Millipore TLC silica gel 60
F254), dried, and eluted with different solvent systems (5:2 ratio of MeOH
to NH4OH [
25% in H2O] for AMK and TOB and 3:2, 25:1, and 15:2
ratios of MeOH to NH4OH [
25% in H2O] for NEO, NET, and SIS,
respectively). AGs were visualized by staining with a cerium molybdate
FIG 1 Inhibition of AAC enzymes by various metal salts with and without physiological concentrations of NaCl. Activities with metal ion inhibitors are
presented as a percentage of the activity of each AAC with AG without metal salts. The clinically relevant AGs AMK, GEN, and TOB are presented here. Other
AGs, KAN, NEO, NET, and SIS, are presented in Fig. S3 in the supplemental material. The asterisk indicates that as AuCl3 precipitated in HEPES (pH 7.5) buffer
with DTDP in the reaction mixture, it was not tested against AAC(6=)-Ib= and AAC(6=)-IId and is therefore not presented in this figure. AAC(6=)-Ib= and
AAC(6=)-IId were also not tested with the Cu2 salts in the presence of 100 mM NaCl due to solubility issues.
Li et al.
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stain [5 g of (NH4)2Ce(NO3)6, 120 g of (NH4)6Mo7O24·4H2O in 10%
H2SO4]. A summary of all themetal-AG-enzyme combinations tested and
the results is presented in Fig. 2.
Determination of potential inhibition mechanism using EDTA. To
investigate whether the inhibition of various AACs by differentmetal ions
is reversible and establish whether AAC enzyme activity could be restored
by sequestering the metal ions from the reactions, we performed assays
with EDTA, which served as a strong metal ion scavenger (see Fig. S4 in
the supplemental material). Reaction mixtures (200 l) contained metal
salt (1 mM), AG (100 M), AcCoA (150 M), DTNB (2 mM), EDTA (2
M, pH 8.0), and AAC(3)-Ib (0.5 M) or AAC(3)-IV (0.125 M). Reac-
tionswere carried out in 50mMMES, pH6.6. TheAAC(3)-Ib enzymewas
tested with SIS and the metal salts Cu(OAc)2, ZnCl2, and AuCl3.
AAC(3)-IV was tested with TOB and the salts Cu(OAc)2, ZnCl2, CdSO4,
and AuCl3. After the addition of the enzyme, the absorbance of each
reactionwas recorded every 30 s for 20min (see Fig. S4). All reactionswere
performed in triplicate. Three control reactions were performed in which
the following components were lacking: (i) EDTA (which represented the
inhibited reactions), (ii) EDTA and metal salts (which represented the
standardN-acetylation reactions of AGs by AACs to which all other reac-
tions were compared in this study), and (iii) EDTA and AGs (which
showed that the metal salts did not interfere with the assay conditions).
Inhibition of AACs bymetal salts at near-physiological salt concen-
tration. To establish if the metal inhibition of AACs is unaffected by the
salt concentration found physiologically, experiments were performed in
the presence of 100 mM NaCl. Experiments with Cu2 and Zn2 were
performed as described above for each enzyme, except for Eis, as its activ-
ity is inhibited in the presence of salt and therefore was not tested with
NaCl. AAC(6=)-Ib= and AAC(6=)-IId were not tested with the Cu2 salts
in the presence of NaCl due to solubility issues. Results of these control
experiments are presented in Fig. 1 (see also Fig. S3 in the supplemental
material).
Determination of IC50s by UV-Vis assays. For selected metal salts
that showed complete inhibition of theAACactivities against certainAGs,
FIG2 TLCsmonitoring the acetylation of various AGs (AMK,NEO,NET, SIS, and TOB) by different AACs in the presence ofmetal salts. Note that details about
AG, AAC, metal salt, and Rf values are provided for each line on the TLCs. The expected and observed enzyme activities are also provided.
Inhibition of AACs by Metal Salts
July 2015 Volume 59 Number 7 aac.asm.org 4151Antimicrobial Agents and Chemotherapy
 o
n
 August 23, 2016 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
we determined the 50% inhibitory concentrations (IC50s) in combination
with the correspondingAGs. Assayswere performed in 96-well plateswith
DTNBorDTDPas indicators for specific enzymes as described above. The
metal salts were dissolved in appropriate buffers (100l) for each enzyme,
and a 5-fold dilution was performed, making the final concentration of
themetal salts range from 2.6 pM to 1mM in the assay. AG and enzyme in
buffer (50l) were then added into each well and incubated for 10min to
allow potential positioning or binding of the substrate and/or inhibitor
into the enzyme active site. Reactions were then initiated by the addition
of AcCoA and indicator (50 l). Reactions with AAC(6=)-Ie were per-
formed at 37°C. All other enzymatic reactions were performed at 25°C.
Absorbance at 412 nm (for DTNB) or 324 nm (for DTDP) was recorded
every 30 s for 20min. Initial rates of reactionwere calculated using the first
10 min of the reaction and expressed as a percentage of the rate of the
reaction mixture containing no metal salt inhibitors. IC50s were then cal-
culated using a Hill plot fit with Kaleidagraph 4.1. Experiments were per-
formed in duplicate or triplicate. The data with standard errors are sum-
marized in Table 2, and a sample graph for the IC50 of AuCl3 against Eis
with NET is presented in Fig. S5 in the supplemental material.
Determination of MIC values for combinations of metals and AGs.
MIC values were determined using the double-microdilution method.
Various concentrations of AGs were combined with different concentra-
tions of ZnPT (0 to 80M), and bacteriawere grown for 16 h prior toMIC
value determination. The AG concentrations used varied with each bac-
terial strain as follows: AMK at 0.06 to 32g/ml withA. baumanniiATCC
19606, 0.25 to 128g/ml with isolate 75, and 0.015 to 8g/ml with isolate
81; 0.063 to 16 g/ml with E. cloacae ATCC 13047, 0.015 to 8 g/ml with
isolate 41, 0.004 to 2 g/ml with isolate 52, and 0.015 to 8 g/ml with
isolate 61; 0.031 to 16g/mlwithK. pneumoniaeATCC27736, 0.125 to 64
g/ml with isolate 22, 0.031 to 16 g/ml with isolate 24, 0.004 to 2 g/ml
with isolate 34, and 0.031 to 16 g/ml with isolate 44; TOB at 0.031 to 16
g/ml with A. baumannii ATCC 19606, 0.015 to 8 g/ml with isolate 75,
and 0.004 to 2 g/ml with isolate 81; 0.008 to 4 g/ml with E. cloacae
ATCC 13047, 0.015 to 8 g/ml with isolate 41, 0.015 to 8 g/ml with
isolate 52, and 0.015 to 8 g/ml with isolate 61; 0.031 to 16 g/ml with K.
pneumoniae ATCC 27736, 0.25 to 128 g/ml with isolate 22, 0.25 to 128
g/ml with isolate 24, 0.0006 to 0.3g/ml with isolate 34, and 0.25 to 128
g/ml with isolate 44. For combinational studies, the concentration of
AGs was varied horizontally on the plate, while the metal concentration
was varied vertically on the plate. Observed bactericidal concentrations
were then compared to that of AG or ZnPT (Tables 3 and 4). For the
strains that showed observable synergistic effect between ZnPT and AGs
(A. baumannii ATCC 19606 and K. pneumoniae ATCC 27736, as pre-
sented in the isobolograms of Fig. 3), we further performed determination
ofMIC values of AGs or ZnPT alone in the presence of 25mg/ml of bovine
serum albumin (BSA; data not shown), as well as AGs in combination
with ZnPT in the presence of BSA (see Tables S2 and S3 in the supplemen-
tal material).
RESULTS
In vitro inhibition of AACs by metal salts. To determine the
inhibitory effect of different metal salts on the N-acetylating ac-
tivity of AACswith various AGs, we first performedUV-Vis assays
in 96-well plates (Fig. 1; see also Fig. S3 and Table S1 in the sup-
plemental material). Among the metal ions (Mg2, Cr3, Cr6,
Mn2, Co2, Ni2, Cu2, Zn2, Cd2, and Au3) selected, Cu2
salts [Cu(OAc)2, Cu(NO3)2, and CuSO4] showed the most inhib-
itory activity against AACs in general. The presence of Zn2 and
Cd2 ions also resulted in generally lower AAC activity, with the
exception of AAC(2=)-Ic, which was not well inhibited by Zn2 or
Cd2. Eis also seemed to remain uninhibited by Zn2 salts when
tested with AMK and by ZnSO4 when tested with other AGs. Ac-
TABLE 2 IC50s for the various metal ions that have shown complete
inhibition in UV-Vis assays against various AACs in combination with
different AGs
Enzyme AG Metal ion IC50 (M)
AAC(2=)-Ica GEN AuCl3 12 3
AAC(3)-Iaa GEN ZnCl2 1.4 0.3
AAC(3)-Iba SIS ZnCl2 0.13 0.02
ZnSO4 1.4 0.2
AAC(3)-IVa NEO ZnCl2 44 19
Zn(OAc)2 34 8
ZnBr2 17 5
CdCl2 7.3 2.7
NET CdSO4 8.7 1.7
TOB CuSO4 0.35 0.14
AAC(6=)-Ib=b AMK CdSO4 0.41 0.08
AuCl3 0.41 0.07
SIS Zn(OAc)2 7.8 1.7
AAC(6=)-Iea SIS ZnBr2 0.41 0.08
TOB ZnSO4 5.2 1.3
Eisa KAN AuCl3 7.7 2.3
NET AuCl3 18 1
SIS CdCl2 0.78 0.09
CdSO4 0.79 0.10
AuCl3 121 26
TOB Zn(OAc)2 0.04 0.01
CdCl2 0.41 0.03
AuCl3 0.010 0.003
a Reactions were monitored by recording the absorbance at 412 nm with DTNB.
b Reactions were monitored by recording the absorbance at 324 nm with DTDP.
TABLE 3MICs of AMK (g/ml) in the presence of various concentrations of ZnPT against various Gram-negative bacterial strains
ZnPT concn (M)
MIC of AMK (g/ml) against strain:
A. baumannii E. cloacae K. pneumoniae
ATCC
19606
Isolate
75
Isolate
81
ATCC
13047
Isolate
41
Isolate
52
Isolate
61
ATCC
27736
Isolate
22
Isolate
24
Isolate
34
Isolate
44
80 0.06 NGa NG NG NG NG NG NG NG NG NG NG
40 0.06 NG NG NG NG NG NG 0.5 NG NG NG NG
20 0.25 0.25 0.25 NG NG NG 4 0.5 NG 4 NG NG
10 0.5 128 1 0.5 1 NG 4 2 8 4 NG NG
5 2 128 2 2 8 1 4 4 8 4 0.25 1
2.5 2 128 1 2 8 2 8 8 32 8 0.5 16
1.25 2 128 1 2 8 2 8 8 32 16 0.5 16
0 4 128 4 2 8 2 8 16 32 16 2 16
a NG, no growth.
Li et al.
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tually, AAC(2=)-Ic was, in general, effectively inhibited only by
Cu2 and Au3. Interestingly, we noted that in general Ni2
(NiCl2 and NiSO4) exerted moderate inhibition against the
AAC(6=) enzymes but not AAC(6=)-Ie (when tested with KAN or
NEO) or other AACs. On the other hand, Au3 inhibited all AACs
tested, with the exceptions of AAC(6=)-Ie where only 6=-N-acety-
lation of KAN was inhibited and AAC(3)-Ib in the presence of
GEN and SIS where 3-N-acetylation was not inhibited. We also
exploredwhether different anions affected the inhibitory ability of
the same metal cation, yet with the Ni2, Zn2, Cu2, and Cd2
ions that we tested in different salt forms, we did not observe a
noticeable difference in the enzyme activities among the different
anions. Additionally, with few exceptions, we did not observe a
difference in the metals’ inhibitory effect among various AGs
across all enzymes studied. In addition, Eis showed the most re-
duction in activity in response to Au3, which made Au3 more
effective as an inhibitor for Eis than Cd2 and some Zn2 salts. It
was also noticeable that ZnSO4 did not inhibit Eis activity asmuch
as the other Zn2 salts did when tested with other AGs. This trend
was also observed with AAC(3)-IV, suggesting that the SO4
2 ion
may deteriorate the inhibitory effect of Zn2. For the different
AAC(3) enzymes, Zn2 and Cd2 showed the second-best inhib-
itory effect after Cu2, even though the AAC(3)-IV activity was
higher when tested with ZnSO4 than when tested with other Zn
2
salts. Au3 was also found to exert decent inhibition of the
AAC(3) enzymes with the exception of AAC(3)-Ib when tested
with GEN and SIS.
Some metals involved in this study may have high affinity for
free thiols andmight potentially bind to the releasedCoASH faster
than the indicator (DTNB) to form a metal-thiol complex, giving
false-positive results for inhibition in the UV-Vis assays. Thus, we
performed TLC experiments to confirm that the inhibition ob-
served inUV-Vis assays was real inhibition of the acetyltransferase
activity.We selected onemetal-AG-enzyme combination as a rep-
resentative for each metal salt. For the metals that we tested with
different counter ions, we tested all different salt forms for Zn2
salts and SO4
2 salts for other metals [as well as Cu(NO3)2]. As
expected, we found that the reactions withmetal salts that showed
good inhibition in UV-Vis assays [Cu2, Zn2, Cd2, Ni2 with
AAC(6=)s only, and Au3] showed no generation of acetylated
AGs, whereas the reactions with other metals that showed no in-
hibition in UV-Vis assays (Mg2, Mn2, Cr3, Cr6, and Co2)
also suggested no inhibition of the AAC activities (Fig. 2).
To investigate if the metal salts would react similarly under
physiological conditions, we tested our best overall inhibitor can-
didates, Cu2 and Zn2 salts, in the presence of 100 mM NaCl
(Fig. 1; see also Fig. S3 in the supplementalmaterial).We observed
no significant difference between the enzyme activities with and
without physiological concentrations of NaCl in the presence of
different metal ions. AAC(6=)-Ie, as well as AAC(6=)-Ib= and
AAC(6=)-IId (with Zn2 salts), showed complete inhibition when
tested against AMK and KAN in the presence of NaCl, indicating
that under physiological conditions thesemetal salts could be even
better inhibitors. It is important to note that AAC(6=)-Ib= and
AAC(6=)-IId were not tested with Cu2 salts due to solubility is-
sues.
We next determined the half-maximum inhibitory concentra-
tion (IC50) values for selected salts that showed complete inhibi-
tion in our UV-Vis assays (Table 2; see also Fig. S5 in the supple-
mental material). With the exception of AAC(3)-IV in the
presence of NEOwhere the IC50s for ZnCl2, Zn(OAc)2, and ZnBr2
were 44 19M, 34 8M, and 17 5M, respectively, Zn2
salts were found to display low IC50s ranging from0.04 0.01M
to 7.8  1.7 M against all enzymes. For the inhibition of
AAC(3)-IV byCd2 salts, IC50s of 7.3 2.7Mand 8.7 1.7M
were determined for CdCl2 in the presence of NEO and CdSO4 in
the presence of NET, respectively. Cd2 salts were found to be
much better inhibitors of AAC(6=)-Ib= and Eis with IC50s ranging
from 0.41  0.03 M to 0.79  0.10 M. AuCl3 was found to
display the widest range of IC50s (0.010 0.003 M to 121 26
M).
Finally, to elucidate the potential mechanism by which these
metal ions inhibit the AAC activities, we tested whether the effect
that metal ions exert on AAC activity is reversible. We added
EDTA to the reactionmixtures to chelate the metal inhibitors and
found that the presence of EDTA can restore enzyme activity
against AG substrates, potentially by chelating the metal ions and
preventing them from interfering with the enzymatic reaction be-
tween the AACs and AGs (see Fig. S4 in the supplemental mate-
rial).
Activity of AGs in combination with ZnPT in various bacte-
rial strains. Since Zn2 was overall a great metal ion inhibitor in
our study, we decided to further investigate Zn2 for its effect on
theMIC values of AMKor TOB against strains ofA. baumannii, E.
cloacae, and K. pneumoniae. After discovering that ZnCl2 had no
effect on the MIC values of AMK and TOB against A. baumannii,
TABLE 4MICs of TOB (g/ml) in the presence of various concentrations of ZnPT against various Gram-negative bacterial strains
ZnPT concn (M)
MIC of TOB (g/ml) against strain:
A. baumannii E. cloacae K. pneumoniae
ATCC
19606
Isolate
75
Isolate
81
ATCC
13047
Isolate
41
Isolate
52
Isolate
61
ATCC
27736
Isolate
22
Isolate
24
Isolate
34
Isolate
44
80 NGa NG NG NG NG NG NG NG NG NG NG NG
40 0.0313 NG NG NG NG NG 8 0.0313 NG NG NG NG
20 0.0313 NG NG NG 8 NG 8 0.0313 NG NG NG NG
10 0.0313 NG NG 1 8 4 8 0.0313 8 4 NG 8
5 0.5 8 1 1 8 4 8 0.5 128 128 0.0094 128
2.5 0.5 8 1 1 8 8 8 0.5 128 128 0.038 128
1.25 1 8 1 1 8 8 8 0.5 128 128 0.075 128
0 1 8 2 1 8 8 8 2 128 128 0.038 128
a NG, no growth.
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possibly due to poor intracellular Zn2 concentration, we decided
to use ZnPT, an organic zinc complex, which was previously re-
ported to have improvedmembrane permeability (16). This study
showed that the presence of ZnPT significantly reduced the MIC
values of AMK and TOB inmost of the 12 bacterial strains that we
tested (Tables 3 and 4).
AgainstA. baumanniiATCC19606 as well as clinical isolate 81,
theMIC value of AMKwas reduced from4g/ml to 0.25g/ml in
the presence of 20 MZnPT (Table 3). With the same amount of
ZnPT, the MIC value of AMK was reduced from 128 g/ml to
0.25 g/ml against A. baumannii clinical isolate 75. The same
trend held true against the E. cloacae and K. pneumoniae strains.
Against E. cloacae clinical isolate 41, the MIC value of AMK was
reduced from 8g/ml to 1g/ml in the presence of 10MZnPT.
Against the other strains (E. cloacae ATCC 13047, isolate 52, and
isolate 61), theAMKMICvalueswere reduced from2g/ml to 0.5
g/ml, from2g/ml to 1g/ml, and from8g/ml to 4g/ml
in the presence of 5 to 10MZnPT, respectively. AgainstK. pneu-
moniae strains, 4- to 32-fold reductions in theMIC values of AMK
were observed in the presence of 5 to 20 M ZnPT.
The reduction in MIC values in the presence of ZnPT was also
observed for TOB against most strains tested (Table 4). Against
the different A. baumannii strains, the MIC values of TOB were
reduced from 1 g/ml to 0.0313 g/ml (ATCC 19606), and
from 2 g/ml to 1 g/ml (clinical isolate 81) in the presence of 10
M and 1.25 M ZnPT, respectively. Yet, against clinical isolate
75, the MIC value of TOB went from 8 g/ml to no growth in
the control wells, suggesting that ZnPT had no effect on the MIC
of TOB in this strain. This was similarly observed againstE. cloacae
ATCC 13047 and clinical isolates 41 and 61. Against the E. cloacae
clinical isolate 52, the MIC value of TOB was reduced from 8
g/ml to 4g/ml with 5MZnPT. AgainstK. pneumoniaeATCC
27736 and clinical isolates 22, 24, and 44, 10 MZnPT effectively
reduced the MIC values of TOB from 2 g/ml to0.0313 g/ml,
from 128 g/ml to 8 g/ml, from 128 g/ml to 4 g/ml, and
from128g/ml to 8g/ml, respectively. AgainstK. pneumoniae
clinical isolate 34, the MIC value of TOB was reduced from 0.038
g/ml to 0.0094 g/ml in the presence of 5 M ZnPT. With the
two strains that showed synergy between AGs and ZnPT (A. bau-
manniiATCC19606 andK. pneumoniaeATCC27736 [Fig. 3]), we
supplemented themediumwith 25mg/ml BSA and found that the
presence of BSA did not change theMIC of AMK, TOB, and ZnPT
alone (data not shown). When testing the MIC of AG in combi-
nation with ZnPT with supplemented BSA, we found that ZnPT
still decreased the MIC of AGs in K. pneumoniae ATCC 27736
from 16 g/ml to 0.25 g/ml for AMK (see Table S2 in the sup-
plemental material) and 8 g/ml to 0.06 g/ml for TOB. How-
ever, the same effect was not observed in A. baumannii ATCC
19606 (see Table S3).
DISCUSSION
To investigate their inhibitory effect on eight AACs, we tested a
panel of nine metal ions (in different salt forms) and studied their
interference in modifying seven AGs (AMK, GEN, KAN, NEO,
NET, SIS, and TOB) (Fig. 1; see also Fig. S3 and Table S1 in the
supplemental material). By UV-Vis assays, we demonstrated that
Cu2 is overall the best at inhibiting the different AACs studied.
We found Zn2 and Cd2, which also showed significant inhibi-
tion of most enzymes, to be the second-best candidates as AAC
inhibitors. Inhibition of AAC activity by Cu2, Zn2, Cd2, Ni2
with AAC(6=)s only, and Au3was also confirmed by TLC studies
(Fig. 2). Some negative controls were also performed during the
TLC experiments.
Althoughmetal saltswere found to be good inhibitors ofAACs,
the inherent toxicity of some of these metals can render them less
desirable regardless of their high inhibitory effect. Despite Zn2
salts falling short in their inhibitory ability compared to Cu2
salts, Zn2 salts remain more desirable for their potential devel-
opment into clinical AAC inhibitors as they are among the least
toxic metal salts based on 50% lethal dose (LD50) values [e.g., 794
mg/kg of body weight in rats by oral intake for Zn(OAc)2 com-
FIG 3 Isobolograms showing the synergistic effect between ZnPT and AMK
or TOB in A. baumannii ATCC 19606 and K. pneumoniae ATCC 27736.
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pared to 501 mg/kg for Cu(OAc)2 and 1,710 mg/kg in rats by oral
intake for ZnSO4 compared to 361 mg/kg for NiSO4, 482 mg/kg
for CuSO4, and 280 mg/kg for CdSO4]. Even though Zn
2 and
Cd2 showed similar inhibitory activities in vitro and displayed
similar ranges of IC50s (0.04 0.01 M to 44 19 M for Zn
2
salts compared to 0.41 0.03 M to 8.7 1.7 M for Cd2 salts
[Table 2]), Zn2 salts remain more clinically relevant, as Cd2
salts display higher toxicity (LD50 values of 107 mg/kg and 280
mg/kg for CdCl2 and CdSO4, respectively, in rats by oral intake).
It is known that Cl salts are inherently more toxic than some
other salt forms.Within the Zn2 salt family, the toxicity of ZnCl2
and Zn(OAc)2 [LD50 values of 359 mg/kg, 794 mg/kg, 1,447 mg/
kg, and 1,710 mg/kg for ZnCl2, Zn(OAc)2, ZnBr2, and ZnSO4,
respectively, in rats by oral intake] and the failure of the less toxic
ZnSO4 at inhibiting some AACs render ZnBr2 the most desirable
among the Zn2 salts studied.Within the Cu2 salts, NO3
 seems
to be a safer counter ion than SO4
2 andOAc [LD50 values of 482
mg/kg, 501 mg/kg, and 940 mg/kg for CuSO4, Cu(OAc)2, and
Cu(NO3)2, respectively]. As for gold salts, even though gold is
generally known to be toxic and expensive, it is currently part of
therapies for diseases such as rheumatoid arthritis (31). Given that
no other metal ions worked as well as gold at inhibiting the
AAC(2=)-Ic enzyme, gold should not be dismissed as a potential
candidate to combat the resistance associated with this enzyme.
Having established Zn2 salts as top candidates for AAC inhi-
bition, we set to determine their effect on the activity of AGs in
various bacterial strains of A. baumannii, E. cloacae, and K. pneu-
moniae. Prior to working in bacterial cells, we demonstrated that
the presence of NaCl, at a concentration mimicking that under
physiological conditions, did not interfere with the inhibitory ef-
fect of the metal ion salts on AACs (Fig. 1; see also Fig. S3 in the
supplemental material). We also showed that in the presence of
EDTA, the inhibitory effect of themetal ions on theAACs could be
reversed as EDTA, a strongmetal-chelating agent, sequestered the
metal ions from the enzymatic reactions (see Fig. S4).
Within each bacterial species selected for our studieswithZn2
salts, we included one commercially purchased ATCC strain as
well as a few clinical isolates. We chose some clinical isolates dis-
playing susceptibility to the three commonly prescribed AGs
(AMK, GEN, and TOB) and some displaying resistance to these
drugs (Table 1). Overall, all clinical isolates selected displayed a
complex resistance profile to a variety of clinically relevant antibi-
otics, including different classes and generations of -lactams,
fluoroquinolones, tetracycline, etc.
When we tried to determine the MIC values of AMK and TOB
againstA. baumannii in the presence of ZnCl2, we quickly realized
that the Zn2 salts studied had no effect on theMIC values of these
AGs. We postulated that this could possibly be due to poor intra-
cellular Zn2 concentration resulting from the poor membrane
permeation of these salts. We therefore decided to use ZnPT, a
membrane-permeant organic zinc complex. We found ZnPT to
significantly reduce the MIC values for both AGs in most strains
tested. Of the A. baumannii strains, ATCC 19606 and clinical iso-
late 81 are both susceptible to AMK. Cotreatment with 40 M
ZnPT reduced the MIC value of AMK by 67-fold against the
ATCC 19606 strain, whereas using 20MZnPT reduced theMIC
value of AMK by 16-fold against clinical isolate 81. The most sig-
nificant effect was observed against clinical isolate 75, which was
resistant to AMK (128 g/ml) and became highly sensitive to
this AG (0.25g/ml) in the presence of 20MZnPT. Against E.
cloacae and K. pneumoniae strains, which were all sensitive or dis-
played intermediate levels of resistance to AMK to start with, the
MIC values of AMK showed as much as a 32-fold reduction with
20 MZnPT. The resistance profile to TOB is different from that
to AMK in the strains that we studied. Most of the K. pneumoniae
strains (isolates 22, 24, and 44) are resistant to TOB while ATCC
27736 and clinical isolate 34, as well as all A. baumannii and E.
cloacae strains, are susceptible to this AG. Although not as signif-
icant as those observed in AMK, the reductions in the MIC values
of TOB were still observed against most of these strains. We
looked for potential synergistic effects between AGs and ZnPT
and observed strong synergy between AMK or TOB and ZnPT in
A. baumannii ATCC 19606 and K. pneumoniae ATCC 27736 as
suggested by the isobolograms presented in Fig. 3. Since AGs are
given intravenously when used to treat systemic infections, we
further supplemented themediumwithBSA in ourMIC studies in
order to see whether the ZnPT can still enhance AG actions in the
two strains above in amore complex environment thatmimics the
blood. With this more complex system, ZnPT still significantly
reduced the MIC of AMK and TOB in K. pneumoniae ATCC
27736. However, this effect was not retained in A. baumannii
ATCC 19606 (see Tables S2 and S3 in the supplemental material).
In sum, we showed that Zn2 and other metal ions are capable
of inhibiting the AG N-acetyltransferase activity of a variety of
AACs in vitro. Developing metal salts into AAC inhibitors for
combinatorial therapies with AGs is potentially a promising ave-
nue for improving the clinical outcomes of AGs in treatment of
resistant bacterial infections resulting from the action of AAC en-
zymes. Themechanism(s) by which thesemetal ions inhibit AACs
is still unknown. Future studies, outside the scope of this article,
aimed at elucidating the potential mechanism(s) underlying this
inhibition would further enhance our understanding and help
combat bacterial resistance in clinical therapeutic regimens.
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